TISIDB

Summary
Symbol	LPCAT2
Name	lysophosphatidylcholine acyltransferase 2
Aliases	FLJ20481; AGPAT11; AYTL1; acyltransferase like 1; 1-AGP acyltransferase 11; 1-AGPAT 11; 1-acylglycerol-3-pho ......
Chromosomal Location	16q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Endoplasmic reticulum membrane Single-pass type II membrane protein Golgi apparatus membrane Single-pass type II membrane protein Lipid droplet
Domain	PF01553 Acyltransferase PF00036 EF hand PF13202 EF hand
Function	Possesses both acyltransferase and acetyltransferase activities. Activity is calcium-dependent. Involved in platelet-activating factor (PAF) biosynthesis by catalyzing the conversion of the PAF precursor, 1-O-alkyl-sn-glycero-3-phosphocholine (lyso-PAF) into 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (PAF). Also converts lyso-PAF to 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine (PC), a major component of cell membranes and a PAF precursor. Under resting conditions, acyltransferase activity is preferred. Upon acute inflammatory stimulus, acetyltransferase activity is enhanced and PAF synthesis increases. Also catalyzes the conversion of 1-acyl-sn-glycero-3-phosphocholine to 1,2-diacyl-sn-glycero-3-phosphocholine.

> Gene Ontology [ TOP ]
Biological Process	GO:0006644 phospholipid metabolic process GO:0006650 glycerophospholipid metabolic process GO:0006663 platelet activating factor biosynthetic process GO:0008654 phospholipid biosynthetic process GO:0036151 phosphatidylcholine acyl-chain remodeling GO:0045017 glycerolipid biosynthetic process GO:0046469 platelet activating factor metabolic process GO:0046470 phosphatidylcholine metabolic process GO:0046474 glycerophospholipid biosynthetic process GO:0046486 glycerolipid metabolic process GO:0097164 ammonium ion metabolic process
Molecular Function	GO:0003841 1-acylglycerol-3-phosphate O-acyltransferase activity GO:0008374 O-acyltransferase activity GO:0016407 acetyltransferase activity GO:0016411 acylglycerol O-acyltransferase activity GO:0016413 O-acetyltransferase activity GO:0016746 transferase activity, transferring acyl groups GO:0016747 transferase activity, transferring acyl groups other than amino-acyl groups GO:0042171 lysophosphatidic acid acyltransferase activity GO:0047144 2-acylglycerol-3-phosphate O-acyltransferase activity GO:0047184 1-acylglycerophosphocholine O-acyltransferase activity GO:0047192 1-alkylglycerophosphocholine O-acetyltransferase activity GO:0071617 lysophospholipid acyltransferase activity
Cellular Component	GO:0005795 Golgi stack GO:0005811 lipid particle GO:0031984 organelle subcompartment GO:0098791 Golgi subcompartment

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa00564 Glycerophospholipid metabolism hsa00565 Ether lipid metabolism hsa01100 Metabolic pathways
Reactome	R-HSA-1482788: Acyl chain remodelling of PC R-HSA-1483206: Glycerophospholipid biosynthesis R-HSA-1430728: Metabolism R-HSA-556833: Metabolism of lipids and lipoproteins R-HSA-1483257: Phospholipid metabolism

Summary
Symbol	LPCAT2
Name	lysophosphatidylcholine acyltransferase 2
Aliases	FLJ20481; AGPAT11; AYTL1; acyltransferase like 1; 1-AGP acyltransferase 11; 1-AGPAT 11; 1-acylglycerol-3-pho ......
Chromosomal Location	16q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between LPCAT2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	LPCAT2
Name	lysophosphatidylcholine acyltransferase 2
Aliases	FLJ20481; AGPAT11; AYTL1; acyltransferase like 1; 1-AGP acyltransferase 11; 1-AGPAT 11; 1-acylglycerol-3-pho ......
Chromosomal Location	16q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of LPCAT2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	Total # shRNA with >= 4-fold: 1	Resistant to T-cell proliferation
24476824	shRNA	melanoma	B16	Secondary screen	Total # shRNA with >= 4-fold: 1	Resistant to T-cell proliferation

Summary
Symbol	LPCAT2
Name	lysophosphatidylcholine acyltransferase 2
Aliases	FLJ20481; AGPAT11; AYTL1; acyltransferase like 1; 1-AGP acyltransferase 11; 1-AGPAT 11; 1-acylglycerol-3-pho ......
Chromosomal Location	16q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of LPCAT2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.424	0.297
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.167	0.92
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.629	0.527
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.794	0.0138
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.759	0.634
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.847	0.633
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.034	0.939
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.451	0.765
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.322	0.858
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.666	0.537
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.246	0.428
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.383	0.00155

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of LPCAT2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	5.9	-5.9	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	33.3	-33.3	0.231
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	2.7	-2.7	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.4	-3.4	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	5.9	-5.9	0.447
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	9.1	-9.1	0.458
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	14.3	-14.3	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	LPCAT2
Name	lysophosphatidylcholine acyltransferase 2
Aliases	FLJ20481; AGPAT11; AYTL1; acyltransferase like 1; 1-AGP acyltransferase 11; 1-AGPAT 11; 1-acylglycerol-3-pho ......
Chromosomal Location	16q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LPCAT2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	LPCAT2
Name	lysophosphatidylcholine acyltransferase 2
Aliases	FLJ20481; AGPAT11; AYTL1; acyltransferase like 1; 1-AGP acyltransferase 11; 1-AGPAT 11; 1-acylglycerol-3-pho ......
Chromosomal Location	16q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LPCAT2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LPCAT2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	LPCAT2
Name	lysophosphatidylcholine acyltransferase 2
Aliases	FLJ20481; AGPAT11; AYTL1; acyltransferase like 1; 1-AGP acyltransferase 11; 1-AGPAT 11; 1-acylglycerol-3-pho ......
Chromosomal Location	16q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LPCAT2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	LPCAT2
Name	lysophosphatidylcholine acyltransferase 2
Aliases	FLJ20481; AGPAT11; AYTL1; acyltransferase like 1; 1-AGP acyltransferase 11; 1-AGPAT 11; 1-acylglycerol-3-pho ......
Chromosomal Location	16q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of LPCAT2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	LPCAT2
Name	lysophosphatidylcholine acyltransferase 2
Aliases	FLJ20481; AGPAT11; AYTL1; acyltransferase like 1; 1-AGP acyltransferase 11; 1-AGPAT 11; 1-acylglycerol-3-pho ......
Chromosomal Location	16q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between LPCAT2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	LPCAT2
Name	lysophosphatidylcholine acyltransferase 2
Aliases	FLJ20481; AGPAT11; AYTL1; acyltransferase like 1; 1-AGP acyltransferase 11; 1-AGPAT 11; 1-acylglycerol-3-pho ......
Chromosomal Location	16q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting LPCAT2 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse LPCAT2